(Q35035133)

5 August 2017

1 reference

title

Efficacy of newer generation antipsychotics in the treatment of schizophrenia (English)

1 reference

5 August 2017

0 references

Tandon R

1

1 reference

5 August 2017

Jibson MD

series ordinal

2

1 reference

5 August 2017

publication date

1 January 2003

1 reference

5 August 2017

published in

Psychoneuroendocrinology

1 reference

5 August 2017

volume

28 Suppl 1

1 reference

5 August 2017

page(s)

9-26

1 reference

The pharmaceutical industry--to whom is it accountable?

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Neurocognitive impairment in schizophrenia and how it affects treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Weight gain with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Underreporting research is scientific misconduct

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Sponsorship, Authorship, and Accountability

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

New atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Pharmacologic treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Prolactin levels and adverse events in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Mild extrapyramidal signs and functional impairment in ageing.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Effects of anticholinergic medication on memory in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Can meta-analyses be trusted?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900110-5

7 January 2021

10.1016/S0306-4530(02)00110-5

Identifiers

DOI

1 reference

5 August 2017

1 reference